Compile Data Set for Download or QSAR
Report error Found 21 Enz. Inhib. hit(s) with all data for entry = 10683
TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559653(US11370803, Compound I-18)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559651(US11370803, Compound I-17a)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559652(US11370803, Compound I-17b)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559655(US11370803, Compound 1-20)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559635(US11370803, Compound I-1)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559641(US11370803, Compound I-7)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559642(US11370803, Compound I-8)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559640(US11370803, Compound I-6)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559645(US11370803, Compound I-11)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559644(US11370803, Compound I-10)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559650(US11370803, Compound I-16)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559647(US11370803, Compound I-13)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559648(US11370803, Compound I-14)
Affinity DataEC50: <50nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559637(US11370803, Compound I-3)
Affinity DataEC50:  125nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559654(US11370803, Compound I-19)
Affinity DataEC50:  125nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559646(US11370803, Compound I-12)
Affinity DataEC50:  125nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559638(US11370803, Compound I-4)
Affinity DataEC50:  600nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559639(US11370803, Compound I-5)
Affinity DataEC50:  600nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559643(US11370803, Compound I-9)
Affinity DataEC50:  600nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559649(US11370803, Compound I-15)
Affinity DataEC50:  600nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM559636(US11370803, Compound I-2)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein. Example compounds were evaluated for inhibition of the human activated kallikre...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent